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Psychotic disorders can be exacerbated by the hor-
monal changes associated with childbirth, but the extent 
to which exacerbations occur with the menstrual cycle is 
unclear. We addressed this issue by conducting a system-
atic review. Embase, Medline, and PsychINFO databases 
were searched for studies that measured exacerbations of 
psychotic disorders in relation to the menstrual cycle. We 
extracted exacerbation measure, definition of menstrual 
cycle phase, and measurement of menstrual cycle phase. 
Standard incidence ratios were calculated for the perimen-
strual phase based on the observed admissions during this 
phase divided by the expected number of admissions if 
the menstrual cycle had no effect. Random effects models 
were used to examine pooled rates of psychiatric admis-
sion in the perimenstrual phase. Nineteen studies, compris-
ing 1193 participants were eligible for inclusion. Eleven 
studies examined psychiatric admission rates, 5 examined 
symptoms scores, 2 examined self-reported exacerbation, 
and 1 examined both admission rates and symptom scores. 
A random effects model demonstrated the rate of admis-
sions during the perimenstrual phase was 1.48 times higher 
than expected (95% CI: 1.31–1.67), with no significant 
heterogeneity detected. Four of six symptom score studies 
reported perimenstrual worsening, but lack of consistency 
in timepoints precluded meta-analysis. Two studies exam-
ining self-reported menstrual exacerbations reported prev-
alences ranging from 20% to 32.4%. Psychiatric admission 
rates are significantly higher than expected during the peri-
menstrual phase. There is some evidence that a worsening 
of psychotic symptoms also occurs during this phase, but 
further research with more precise measurement of the 
menstrual cycle and symptomatology is required.
Key words:  schizophrenia/psychotic disorders/bipolar 
disorder/menstrual cycle/menstruation/menstruation 
disturbances
Introduction
Since the turn of the 19th century, there have been over 27 
confirmed and 200 possible cases of “menstrual psycho-
sis,” whereby brief  psychotic episodes occur in synchrony 
with the menstrual cycle, with complete inter-episode 
remission.1 Hormonal treatments can be used to prevent 
recurrences,2 suggesting a causative pathophysiologi-
cal mechanism involving fluctuating levels of female sex 
hormones. This raises the possibility that among female 
patients with psychosis, there may be a subgroup in which 
the disorder is particularly related to hormonal fluctua-
tions. Alternatively, there may be more subtle menstrual 
cycle-related changes in mental state universally in women 
with psychosis.
The estrogen hypothesis states that estrogen is protec-
tive for psychosis and that a reduction in estrogen can 
worsen or precipitate psychosis.3 The putative neuro-
protective effect of  estrogen is thought to underlie the 
later age of  onset of  psychotic disorders in women than 
men, the rise in incidence of  psychosis in women post-
menopause (following decline in estrogen levels), and 
the greater severity of  psychotic symptoms in late-onset 
psychosis in women than in men.4 Moreover, various 
interventions associated with estrogen withdrawal can 
precipitate episodes of  psychosis. These include termi-
nation of  pregnancy, removal of  a hydatidiform mole, 
withdrawal of  estrogen medication, administration of 
estrogen receptor antagonists, and administration of 
gonadotropin-releasing hormone agonists which inhibit 
estrogen release.5 Similarly, the period following child-
birth results in an abrupt drop in estrogen and proges-
terone levels and carries a 23-fold increase in relative risk 
for affective psychotic episodes.6
Levels of estrogen vary throughout the menstrual 
cycle, typically peaking around the time of midcycle 
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and declining before the start of menses.7 The estrogen 
protection hypothesis predicts that psychotic disorders 
worsen at times in the cycle when estrogen is low, around 
menstruation8 and several narrative reviews assert this 
is indeed the case.3,4,9,10 A  recent meta-analysis pooling 
data across studies of women with psychiatric diagno-
ses (psychotic disorders, affective disorders, drug-related 
disorders) and those with no specific diagnosis (patients 
presenting with self-harm or suicidal behaviors) demon-
strated worse mental health outcomes around the time of 
menstruation.11 However, this study examined a sample of 
women with different psychiatric disorders; the extent to 
which this relationship is evident in those with psychotic 
disorders is not known. In the present study, we sought 
to address this issue by conducting a systematic review 
of the evidence for menstrual exacerbation of psychotic 
disorders and synthesizing the evidence by meta-analysis.
Methods
The study protocol was pre-registered with PROSPERO 
http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42018105320. PRISMA reporting guide-
lines were followed.12
Search Strategy
The search was conducted in duplicate by 2 independent 
researchers (T.J.R.  and V.C.S.), using Medical Subject 
Headings (MeSH) and text words. Medline, Embase, and 
PsychINFO were initially searched using Ovid (Wolters 
Kluwer) from inception to July 2018 with the following 
combinations of subject headings:
• (Schizophrenia OR Bipolar Disorder OR Psychotic 
Disorders) AND
• (Menstruation OR Menstrual Disturbances OR 
Estrogens OR Receptors, Estrogen OR Estradiol OR 
Progesterone OR Follicle Stimulating Hormone OR 
Luteinizing Hormone)
A PubMed search was then performed using the follow-
ing textwords:
• ((psychosis OR psychotic OR schizophr* OR schizoaf-
fective OR bipolar) AND
• (menstrua* OR catamenia* OR estrogen OR oestrogen 
OR estradiol OR oestradiol OR estrus OR oestrus OR 
monthly OR cyclical OR menses OR periodical OR 
periodic OR luteal OR follicular OR ovulation))
Reference lists of previous reviews3,9–11,13 were manually 
examined to identify additional papers of relevance.
Selection Criteria
Inclusion Criteria. (1) original research of human par-
ticipants; (2) English language; (3) sample sizes of 10 or 
more; (4) studies of any psychotic disorder including: 
schizophrenia, schizoaffective disorder, schizophreni-
form disorder, psychotic disorder not otherwise specified, 
bipolar disorder with psychotic symptoms, depressive 
disorder with psychotic symptoms (with no restrictions 
on the diagnostic classification system used); and (5) 
studies measuring phase of menstrual cycle in relation to 
exacerbation of the disorder.
Exclusion Criteria. (1) case reports, case series, conference 
abstracts, and reviews; (2) studies which only measured 
menstruation abnormalities rather than exacerbation of 
the disorder; (3) studies measuring only premenstrual 
tension symptoms; and (4) studies exclusively of healthy 
volunteers.
Data Extraction
The following variables were extracted from each study: 
author, year of publication, setting, study population, 
sample size, ethnicity, age, study design, diagnosis, diag-
nostic instrument, measurement of psychosis exacer-
bation, measurement of menstrual cycle, definition of 
menstrual cycle phases. Study design was determined 
for the outcome of interest (which may differ from the 
study design of the overall study). For studies measur-
ing symptom scores, we extracted symptom rating scale 
and the timepoints of assessment. For studies measuring 
self-reported exacerbation, we extracted method of self-
report. Data were extracted independently by 2 research-
ers (T.J.R. and V.C.S.) with disagreements discussed with 
a senior researcher (A.E.C.).
Definition of Menstrual Cycle Phase
Consistent with previous meta-analyses14 we standard-
ized to a 28-day cycle where day 1 was defined as the first 
day of menstruation and day 24–day 5 was pre-specified 
as the perimenstrual phase. While we initially intended 
to analyze the premenstrual phase (day 24–day 28) and 
menstrual phase (day 1–day 5) separately, as per Jang and 
Elfenbein,11 this was not possible because only 3 studies 
distinguished between these phases.
Risk of Bias Assessment
Studies were assessed independently for quality using 
a modified version of the Newcastle-Ottawa Scale15 by 
2 study authors (T.J.R.  and V.C.S.) with disagreement 
resolved by a senior author (A.E.C.). This measure pro-
vides separate assessment criteria for cross-sectional, 
case-control, and cohort studies. Consistent with previ-
ous meta-analyses by our group,16 scoring criteria were 
amended such that the maximum score available for each 
study design was 8 to facilitate comparison across study 
designs, see supplementary material.
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Data Synthesis
We planned separate meta-analyses for 3 outcomes of 
interest identified by pilot searches: (1) rate of psychiat-
ric admissions during the perimenstrual phase relative 
to the non-perimenstrual phase; (2) change in symptom 
measures across menstrual cycle phases; and (3) point 
prevalence of self-reported menstrual exacerbation of 
psychotic symptoms. Meta-analysis was performed for 
outcomes reported in 5 or more studies, which meant we 
were only able to examine hospital admissions.
Consistent with previous meta-analyses,11 the rate of 
psychiatric admissions during the perimenstrual phase 
relative to the non-perimenstrual phase was examined 
using pooled standardized incidence ratios (SIR). The 
SIR was defined as the observed count of admissions 
during the phase of interest (O) divided by the expected 
number of admissions during that period (E), where it is 
assumed that expected probability of admission on any 
given day of the menstrual cycle is uniform if  there is 
no association between menstrual phase and admission. 
Prior to analyses, individual study data were standard-
ized to a pre-defined phase definition (perimenstrual: day 
24–day 5 and non-perimenstrual: day 6–day 23), using the 
procedure described by Jang and Elfenbein.11 Specifically, 
for studies that examined more than 2 phases, this 
involved aggregating data across phases so that the phase 
definitions approximated those used in the current study 
(ie, day 24–day 5 vs day 6–day 23). As this standardiza-
tion procedure did not always generate phases that corre-
sponded exactly with our pre-defined phases of interest, 
we computed a deviance score for each study represent-
ing the difference in days between the pre-defined phases 
of interest and those employed in the original study. For 
example, a study examining admissions between day 25–
day 4 vs day 5–day 24 would have a deviance score of 2 
on account of the fact that day 26 and day 5 were not 
included in the phase of interest, but instead included in 
the non-perimenstrual phase. Deviance scores were abso-
lute values based on the rationale that effect sizes would 
be attenuated regardless of whether the phase definitions 
used in the original study was longer or shorter than our 
pre-defined perimenstrual phase. Meta-regression analy-
sis was then used to examine the effect of these scores. 
SIRs and associated standard errors were computed for 
the perimenstrual phase where ratios greater than 1 indi-
cate a greater rate of the outcome than would be expected 
in that phase. SIRs and standard errors were log trans-
formed prior to performing meta-analyses to produce a 
pooled SIR for the perimenstrual phase with 95% CI used 
to determine whether SIRs significantly differ from 1.
Meta-analysis
Meta-analyses were performed on data extracted 
from papers examining admission rates across the 
perimenstrual phase; all analyses were performed in 
Stata 15.17 We used the “meta” command to perform 
random-effects meta-analyses on log-transformed SIRs.18 
This command uses inverse-variance weighting and has 
the advantage of enabling analyses to be conducted for 
user-defined effect sizes (in this case, SIRs). The influence 
of individual studies was estimated using the “metainf” 
command which omits each study in turn from the meta-
analysis to determine the effect on the pooled SIR. We 
then conducted meta-regression to determine the effect 
of the following variables: (1) year of study; (2) deviance 
score (described above); (3) study quality score; and (4) 
diagnosis (comparing schizophrenia with a more broadly 
inclusive psychosis spectrum diagnoses).
Results
After screening for eligibility, 19 full-text articles including 
1193 participants met inclusion criteria (supplementary 
material). Eleven studies examined admission rates,19–29 5 
symptom scores,30–34 2 self-reported exacerbation,35,36 and 
1 examined both admission rates and symptoms scores.37 
When categorized according to the outcome of interest, 
14 studies were cross-sectional19–29,35–37 and 5 were pro-
spective cohort studies.30–34
Admission Rates
Characteristics of the 12 studies examining admission 
rates are shown in table 1. All were cross-sectional, with 
1 providing data for 2 independent samples.20 Half  of 
the studies examined schizophrenia specifically, with the 
remainder employing a broader psychosis spectrum diag-
nosis (including affective psychosis, delusional disorder, 
and brief  psychotic disorder). Sample characteristics 
were not well defined; 4 studies provided no information 
on participant age (mean age range: 30.8 to 37.0 y) and 
none reported ethnicity.
Inclusion criteria meant that many women experienc-
ing menstrual irregularity or dysfunction, or those unable 
to give a comprehensive menstrual cycle history were not 
eligible. Eight studies included only women with regular 
menstrual cycles or cycles of typical length19,22,23,26–29,37 
and 4 specifically excluded women who could not pro-
vide accurate details on their last menstrual cycle.20–22,37 
Ascertainment of menstrual cycle phase was generally 
poor. Six studies used self-report (with or without the aid 
of an interview) alone, as their method of ascertaining 
menstrual phase,19,21,23,27–29 2 used a combination of self-
report and observation,20,26 2 used a combination of self-
report and hormone assays to determine phase,24,37 1 study 
used self-report, observation and hormone assays,25 and 1 
did not report measurement method of menstrual phase.22
Eleven of the 12 studies examining admissions data 
(1 including 2 independent samples), provided data that 
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could be examined by meta-analysis. One study,37 which 
reported a significantly higher rate of admissions during 
the luteal phase (day 15–day 28) relative to the follicular 
phase (day 1–day 14), could not be converted to our phase 
of interest (day 24–day 5) and so was not included in the 
meta-analysis. The forest plot of the 11 studies included 
in the meta-analysis is shown in figure  1. A  random-
effects meta-analysis yielded an overall SIR of 1.48 (95% 
CI: 1.31–1.67), indicating an excess of admissions dur-
ing the perimenstrual phases compared with the expected 
rate. There was no significant effect of heterogeneity, 
Cochran’s Q  =  13.846. Meta-regression analyses indi-
cated that year of study, deviance from our pre-specified 
definition perimenstrual phase, study quality or diagnosis 
were not associated with effect sizes (P > .05 for all). The 
influence analysis (“metainf”) indicated that none of the 
studies had a substantial influence on the overall effect 
size (ie, omitting any one of the studies would not change 
the SIR derived).
Risk of bias for each study is reported in table 2. Scores 
ranged from 2 to 7 with a mean of 4.7. Most studies (10/12) 
scored full marks for representativeness, using consecu-
tive psychiatric admissions as the study sample. No study 
reported a power calculation and only Bergemann et al20 
had a large enough total sample size (n  =  285) to sug-
gest that a power calculation was not required. Only one 
cross-sectional study19 scored a point for nonresponders, 
describing participants who were potentially eligible but 
did not take part in their study. Most studies (8/12) scored 
no points for assessment of exposure (that is to say, men-
strual cycle phase), due to reliance on self-report of last 
menstrual period. All bar one study used record-linkage 
to measure admission rates, and so scored maximum 
points for assessment of outcome (11/12), while most 
reported outcomes appropriately (8/12).
Symptom Scores
Studies reporting symptom scores, with a total of 262 
participants, are shown in table  3. Mean age of the 
samples ranged from 29.1 to 36.1. Four studies used a 
narrow diagnosis of schizophrenia while 2 also included 
affective psychoses. Five studies used the Positive and 
Negative Syndrome Scale (PANSS) and one used the 
Brief  Psychiatric Rating Scale (BPRS). Four studies 
reported repeated measures of symptom scores from dif-
ferent timepoints in the cycle, as illustrated in figure  2. 
As shown, there was little consistency in the time-points 
examined, precluding a meta-analysis. Herceg et al37 com-
pared mean symptom scores of participants admitted in 
the follicular phase (day 1–day 14) to those admitted in 
the luteal phase (day 15–day 28), while Bergemann et al31 
reported regression coefficients for changes in PANSS 
scores only, rather than mean symptom scores.
Four studies reported higher symptom scores perimen-
strually30–33 while 2 reported no effect.34,37 Akhondzadeh St
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et  al30 found significantly higher scores in all PANSS 
subscales and lower levels of estrogen and progesterone 
menstrually (day 3), compared with midcycle (day 13) in 
patients with chronic schizophrenia. Choi et al32 reported 
higher total BPRS scores in the premenstrual phase and 
lower levels of estradiol and progesterone, compared with 
the menstrual and post-menstrual phases. However, they 
found no correlation between change in estradiol and 
change in total BPRS scores. Rubin et al33 reported higher 
total PANSS scores in the early follicular phase (day 2–day 
4)  compared with the mid-luteal phase (day 20–day 22), 
but estradiol was not significantly associated with change 
in symptom scores in regression models. Both Herceg 
et al37 and Thompson et al34 reported no differences in total 
PANSS scores between the follicular phase (day 1–day 
14) and luteal phase (day 15–day 28). Interestingly, Herceg 
et al37 found higher estradiol levels in the follicular phase, 
while Thompson et  al34 found higher levels in the luteal 
phase, despite both studies using the same days to define 
these phases. This discrepancy may be attributable to the 
long sampling period of 14 days. Herceg et al37 found no 
correlation between estradiol and total PANSS scores.
Bergemann et al31 was by far the largest study of symp-
tom ratings (n = 125). They reported significant improve-
ment in PANSS scores in the luteal phase (day 20–day 
22), compared with both the menstrual phase (day 2–
day 4)  and the peri-ovulatory phase (day 10–day 12). 
Estradiol levels were lowest in the menstrual phase and 
showed a statistically significant inverse correlation with 
PANSS Positive scores (P < .05).
Only one study systematically measured premenstrual 
tension symptoms, using the daily rating form (DRF).32 
They found a significant correlation between total BRPS 
score and total DRF score in the premenstrual phase 
(Pearson’s correlation coefficient 0.44, P = .05).
The quality of symptom studies was higher than the 
admission studies (table 2); ranging from 4 to 7, with a 
mean of 5.7, from a maximum of 8. None of the 5 cohort 
studies of symptom scores scored marks for represen-
tativeness as they tended to be selected, nonconsecutive 
samples. As they used repeated measures for symptom 
scores at different timepoints with participants effectively 
acting as their own controls, all scored maximum marks 
for matching of exposed and unexposed groups. Most 
(3/5) measured exposure adequately, most (4/5) used 
blinded assessment of outcome and most (4/5) had suf-
ficient time (1 full menstrual cycle) for the outcome to 
occur. Less than half  (2/5) of these studies described par-
ticipants lost to follow-up adequately. The single cross-
sectional study of symptom scores37 lost marks only 
Fig. 1. Pooled standard incident ratios (SIR) of observed/expected rates of psychiatric admissions during the perimenstrual phase (day 
24–day 5) of a 28-day cycle.
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through lacking a power calculation for the sample size 
and description of nonresponders, scoring a total of 6.
Self-Report
Only 2 studies provide data on self-reported menstrual 
exacerbation. Hsiao et  al36 asked participants or their 
families to report exacerbation in relation to the premen-
strual phase and to rank symptoms as mild, moderate or 
severe. Of 50 participants diagnosed with schizophrenia, 
7 (14.0%) had mild exacerbation, 2 (4.0%) had moder-
ate exacerbation, and 1 (2.0%) had severe exacerbation. 
Gleeson et al35 found 45 of 139 (32.4%) participants diag-
nosed with a schizophrenia-spectrum disorder reported 
fluctuation of severity across their cycle at any timepoint.
The quality of self-report studies was low (table  2). 
Gleeson et  al35 used baseline data from a clinical trial, 
which was not likely to be representative of the wider 
patient population, whereas Hsiao et  al36 used a ran-
dom sample of women presenting to outpatient services. 
Neither study justified sample size nor described non-
responders. Neither study used a valid measurement of 
menstrual cycle phase or exacerbation; both simply asked 
participants if  they experienced menstrual worsening of 
their illness. Thus, Gleeson et al35 scored a total of 1 and 
Hsiao et al36 scored 3.
Discussion
This is the first meta-analysis to demonstrate perimen-
strual exacerbation in women diagnosed with a psychotic 
disorder. Specifically, we found evidence of a clear excess 
of psychiatric admissions during the perimenstrual phase 
relative to the non-perimenstrual phase. There was also 
some evidence from studies examining symptoms at mul-
tiple time-points of perimenstrual worsening of psychotic 
symptoms, but this was not consistent across all studies 
and was not amenable to meta-analysis. Prevalence of 
self-reported exacerbation was only reported by 2 studies, 
ranging from 20% to 32.4%. Our findings lend support to 
the estrogen protection hypothesis by showing a worsen-
ing of psychosis at times in the cycle when estrogen levels 
are low.
As an outcome measure, admission to psychiatric hos-
pital is likely to have a low risk of bias as it uses record 
linkage of routine clinical data. Hospitalization has valid-
ity as an outcome measure as it is associated with poorer 
quality of life and severity of psychopathology in patients 
with psychosis.38 Admission due to psychotic relapse is a 
key driver of mental health costs,39 so factors affecting 
admission rates have important health economic implica-
tions. Our results are consistent with Jang and Elfenbein11 
who report increased rate of psychiatric admissions 
Fig. 2. Mean Positive and Negative Syndrome Scale (PANSS) total scores with standard errors from studies reporting symptom scores at 
more than one timepoint. 
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during the premenstrual and menstrual phase irrespec-
tive of diagnosis. Their study reports a smaller SIR of 
1.20 (CI: 1.08–1.33) during the menstrual phase (day 1–
day 5) and 1.13 (CI: 1.01–1.26) during the premenstrual 
phase (day 24–day 28), relative to the expected admission 
rate. The higher SIR reported in our study might imply 
that women with psychotic disorders are particularly 
vulnerable to the effects of the menstrual cycle, more so 
than women with other mental disorders. It also suggests 
that the robust finding of worst mental health outcomes 
around the time of menstruation across psychiatric diag-
nosis could be driven by poor outcomes in the subgroup 
of women diagnosed with psychotic disorders.
There was some overlap in the studies used for each 
meta-analysis, with 7 admissions papers being used for 
both Jang and Elfenbein11 and ours.19,21,23,26–29 Jang and 
Elfenbein11 also report a small but statistically significant 
increase in completed suicides and suicide attempts in the 
menstrual phase. None of our included studies reported 
these outcomes, therefore we are unable to confirm 
whether this also holds for psychotic disorders.
Admission to psychiatric hospital is not synonymous 
with relapse or exacerbation of psychosis; worsening of 
psychotic symptoms will not always result in a hospital 
admission, unless particularly severe. Thus, admissions 
data potentially captures more extreme variation in psy-
chotic symptomatology. While symptom rating scales 
may be a more sensitive and direct measure of illness 
exacerbation, most studies of symptom ratings exam-
ined inpatient samples, with only one being exclusive of 
outpatients. Inpatients would be expected to have more 
severe psychotic symptoms than community populations. 
This reduced variability may hinder the ability to detect 
fluctuations in symptoms across the menstrual cycle.
Unfortunately, heterogeneity in the 6 studies measur-
ing symptoms ratings, precluded meta-analysis of these 
data. Both the definition of perimenstrual phase and the 
comparison time-points varied between studies. Of the 
studies that reported symptom ratings, all compared the 
symptom scores of participants at one time-point with 
one or 2 other time-points. This method of comparing 
symptom scores is a crude measurement which is not 
sensitive to the marked individual inter-cycle variability, 
present even in those women reporting regular cycles.40 
Indeed, both Herceg et al37 and Thompson et al34 com-
pared an average of symptom ratings of day 1–day 14 
to day 15–day 28, which is almost certainly too long to 
interpret whether there are menstrual fluctuations, poten-
tially missing exacerbation over shorter time-periods.
Despite the lack of any cross-study synthesis, there is 
some evidence that menstrual exacerbation of psychotic 
symptoms occurs; 4 of the 6 studies report statistically 
significant changes in symptoms scores across the cycle. It 
is likely that more precise research methodology in track-
ing both menstrual cycle phase and symptoms of psycho-
sis over time will uncover the underlying relationship.
Worsening of psychotic disorders around the time of 
menstruation, when estrogen levels are low, is supportive 
of the estrogen protection hypothesis.41 However, only 
2 studies of admission rates confirmed menstrual cycle 
phase by hormonal assay,25,37 so it is not known whether 
estradiol was indeed low during the perimenstrual phase. 
Studies of symptom scores did measure estradiol levels 
according to menstrual cycle phase and in 4 of 6 stud-
ies found more severe symptoms in low estrogen phases. 
Three studies failed to find a correlation of estradiol lev-
els and symptoms scores,32,33,37 though this may be attrib-
utable to small sample sizes (mean n = 26). The largest 
study of symptom scores,31 with a sample size of 125, did 
detect a significant inverse correlation between estradiol 
and PANSS Positive scores. Moreover, inverse correla-
tions between psychotic symptoms and estradiol levels 
over time have been reported by 3 studies,42–44 which did 
not meet our inclusion criteria as they did not report 
exacerbation of psychosis in relation to menstrual cycle 
phase. It may be that absolute values of estrogen are less 
relevant than the magnitude of decline in estrogen levels 
over a cycle. Only one study, Choi et al,32 examined this 
and showed no significant correlation between change in 
estradiol and change in BPRS scores (Pearson’s correla-
tion coefficient −0.21, P = .30). Likewise, they reported no 
correlation between symptoms and the ratio of estradiol/
progesterone. Nevertheless, the effect of fluctuations in 
estrogen at an individual level warrants further investiga-
tion in larger studies.
It is difficult to draw firm conclusions from the 2 low-
quality studies of self-reported menstrual exacerbation. 
Although both report that a minority of participants 
experience worsening of psychosis menstrually, it is 
possible that participants incorrectly ascribe premen-
strual dysphoric symptoms to an exacerbation of their 
psychotic illness.9 Conversely, a substantial number of 
women with a psychotic disorder may lack insight that 
their symptoms are worsening.45 Thus, self-report is likely 
to be an unreliable measure of true exacerbation of psy-
chotic illness.
Limitations
There are important limitations to our review. Firstly, 
there was no consistent definition of premenstrual or 
menstrual phases across studies, necessitating the cre-
ation of a perimenstrual phase ranging from day 24 to 
day 5 based on a 28-day cycle. One study37 could not be 
included in the meta-analysis because their definition of 
menstrual cycle phases (day 1–day 14 and day 15–28) 
could not be converted into our phase of interest. The 
time-points were largely calculated by the self-report of 
last menstrual period, which is prone to bias.46 Estimation 
of cycle phase may be particularly fallible in women who 
are experiencing an acute relapse in mental state, who are 
prescribed medication that interferes with their cycle or 
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who have irregular cycles; factors relevant to our study 
population.
Most studies (12/19) specifically excluded women with 
irregular cycles, which aids the standardization of data 
to a 28-day cycle. However, as menstrual dysfunction is 
commonplace in psychotic disorders where up to 40% 
report irregular cycles,35 excluding such patients reduces 
the generalizability of results. Another limitation is the 
use of participants with established psychotic disorders, 
rather than those presenting specifically with their first 
episode of psychosis who would be minimally treated. 
In patients taking regular antipsychotic medication, 
menstruation may be affected because of a reduction in 
the dopaminergic inhibition of prolactin.47 Nonetheless, 
hyperprolactinemia has also been reported in antipsy-
chotic naïve patients with schizophrenia,48 suggesting 
dysfunction of the hypothalamic-pituitary-gonadal axis 
is present at illness onset.
We initially planned to include studies of bipolar 
affective disorder with psychotic symptoms. Although 
we identified several studies examining bipolar disorder 
in relation to menstrual exacerbation,49–61 none specified 
whether psychotic symptoms were present. One-third of 
women with bipolar disorder experience a relapse post-
partum,62 suggesting a vulnerability to hormonal fluctua-
tions that merits a further review of the existing research 
on menstrual exacerbation. The only systematic review 
of this topic to date did not conduct a meta-analysis.13
Further Research
Future research should take advantage of  widely used and 
scientifically validated menstrual tracking Smartphone 
apps.63 These offer more detailed assessment of  men-
strual cycles which do not rely simply upon self-report 
of  last menstrual period. This could be done in conjunc-
tion with validated Smartphone measures of  psychotic 
symptoms64 to provide standardized phases of  the men-
strual cycle. Larger sample sizes, of  women who are early 
in their illness, either antipsychotic naïve or minimally 
treated would further reduce the effect of  confounding 
factors associated with chronic psychosis. The impact of 
premenstrual tension symptoms should be considered 
as well as individual variation in sex hormones, includ-
ing estrogen, progesterone, and testosterone. Not only 
would this allow for a more sensitive measure of  men-
strual exacerbation at a greater temporal resolution that 
does not rely on standardization to a 28-day cycle, but 
individual correlations for each participant could also 
be used to identify women prone to menstrual exacer-
bation of  psychosis. This subgroup may thus be more 
prepared to self-manage monthly exacerbations in their 
illness and could benefit from slight increases in anti-
psychotic doses during times of  increased vulnerability. 
They may also be suitable for trials of  novel targeted hor-
monal therapy, utilizing emerging estrogen treatments 
in schizophrenia.65,66 A similar strategy has already been 
employed for women whose epilepsy has been shown to 
be menstrually exacerbated.67 Furthermore, identifying 
whether women whose psychotic illness is vulnerable 
to menstrual fluctuations are subsequently at increased 
risk of  relapse postpartum and postmenopausal (times 
of  declining estrogen levels) could provide impetus for 
novel preventative treatments.
Conclusion
This systematic review and meta-analysis provides robust 
evidence of an excess in admissions for psychotic disor-
ders perimenstrually, in keeping with the estrogen protec-
tion hypothesis. Further research is needed to characterize 
the effect of the menstrual cycle on the symptomatology 
of psychosis, whether there is a subgroup of women who 
individually have a strong correlation between psychotic 
symptoms and menstrual cycles, and whether this sub-
group is amenable to intervention in the form of hor-
monal therapy.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
Acknowledgment
The authors have declared that there are no conflicts of 
interest in relation to the subject of this study.
References
 1. Brockington  I. Menstrual psychosis. World Psychiatry. 
2005;4(1):9–17.
 2. Brockington  IF. Menstrual psychosis: a bipolar disor-
der with a link to the hypothalamus. Curr Psychiatry Rep. 
2011;13(3):193–197.
 3. Riecher-Rössler  A. Oestrogens, prolactin, hypothalamic-
pituitary-gonadal axis, and schizophrenic psychoses. Lancet 
Psychiatry. 2017;4(1):63–72.
 4. Riecher-Rössler A, Butler S, Kulkarni J. Sex and gender dif-
ferences in schizophrenic psychoses-a critical review. Arch 
Womens Ment Health. 2018;21(6):627–648.
 5. Mahé V, Dumaine A. Oestrogen withdrawal associated psy-
choses. Acta Psychiatr Scand. 2001;104(5):323–331.
 6. Bergink  V, Rasgon  N, Wisner  KL. Postpartum psychosis: 
madness, mania, and melancholia in motherhood. Am J 
Psychiatry. 2016;173(12):1179–1188.
 7. Reed BG, Carr BR. The normal menstrual cycle and the con-
trol of ovulation. In: De Groot LJ, Chrousos G, Dungan K, 
et al., eds. Endotext. South Dartmouth, MA: MDText.com, 
Inc; 2000.
 8. Riecher-Rössler A, Kulkarni J. Estrogens and gonadal func-
tion in schizophrenia and related psychoses. Curr Top Behav 
Neurosci. 2011;8:155–171.
 9. Seeman MV. Menstrual exacerbation of schizophrenia symp-
toms. Acta Psychiatr Scand. 2012;125(5):363–371.
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sbz030/5487599 by King's C
ollege London user on 05 N
ovem
ber 2019
Page 12 of 13
T. J. Reilly et al
 10. Clare  AW. The relationship between psychopathology and 
the menstrual cycle. Women Health. 1983;8(2–3):125–136.
 11. Jang  D, Elfenbein  HA. Menstrual cycle effects on men-
tal health outcomes: a meta-analysis. Arch Suicide Res. 
2018;1–21.
 12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA state-
ment for reporting systematic reviews and meta-analyses of 
studies that evaluate health care interventions: explanation 
and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
 13. Teatero  ML, Mazmanian  D, Sharma  V. Effects of the 
menstrual cycle on bipolar disorder. Bipolar Disord. 
2014;16(1):22–36.
 14. Riley  JL III, Robinson  ME, Wise  EA, Price  DD. A meta-
analytic review of pain perception across the menstrual cycle. 
Pain. 1999;81(3):225–235.
 15. Stang A. Critical evaluation of the Newcastle-Ottawa scale 
for the assessment of the quality of nonrandomized studies 
in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
 16. Cullen AE, Holmes S, Pollak TA, et al. Associations between 
non-neurological autoimmune disorders and psychosis: a 
meta-analysis. Biol Psychiatry. 2019;85(1):35–48.
 17. StataCorp. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC; 2017.
 18. Sterne  J, Bradburn  M, Egger  M. Meta-analysis in stata. 
In: Egger M, Davey Smith G, Altman DG, eds. Systematic 
Reviews in Health Care: Meta‐Analysis in Context. 2nd ed. 
London: BMJ Books; 2018:347–369.
 19. Abramowitz ES, Baker AH, Fleischer SF. Onset of depressive 
psychiatric crises and the menstrual cycle. Am J Psychiatry. 
1982;139(4):475–478.
 20. Bergemann  N, Parzer  P, Nagl  I, et  al. Acute psychiatric 
admission and menstrual cycle phase in women with schizo-
phrenia. Arch Womens Ment Health. 2002;5(3):119–126.
 21. Dalton  K. Menstruation and acute psychiatric illnesses. Br 
Med J. 1959;1(5115):148–149.
 22. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G. Influence 
of the menstrual cycle phase on the therapeutic response in 
schizophrenia. Biol Psychiatry. 1994;36(2):137–139.
 23. Glass  GS, Heninger  GR, Lansky  M, Talan  K. Psychiatric 
emergency related to the menstrual cycle. Am J Psychiatry. 
1971;128(6):705–711.
 24. Huber  TJ, Rollnik  J, Wilhelms  J, von  zur  Mühlen  A, 
Emrich HM, Schneider U. Estradiol levels in psychotic disor-
ders. Psychoneuroendocrinology. 2001;26(1):27–35.
 25. Huber TJ, Borsutzky M, Schneider U, Emrich HM. Psychotic 
disorders and gonadal function: evidence supporting the oes-
trogen hypothesis. Acta Psychiatr Scand. 2004;109(4):269–274.
 26. Lande RG, Karamchandani V. Chronic mental illness and the 
menstrual cycle. J Am Osteopath Assoc. 2002;102(12):655–659.
 27. Luggin  R, Bernsted  L, Petersson  B, Jacobsen  AT. Acute 
psychiatric admission related to the menstrual cycle. Acta 
Psychiatr Scand. 1984;69(6):461–465.
 28. Targum SD, Caputo KP, Ball SK. Menstrual cycle phase and 
psychiatric admissions. J Affect Disord. 1991;22(1–2):49–53.
 29. Zola  P, Meyerson  AT, Reznikoff  M, Thornton  JC, 
Concool  BM. Menstrual symptomatology and psychiatric 
admission. J Psychosom Res. 1979;23(4):241–245.
 30. Akhondzadeh S, Mokhberi K, Amini H, et al. Is there a rela-
tionship between estrogen serum level and symptom severity 
throughout the menstrual cycle of patients with schizophre-
nia? Therapy. 2005;2(5):745–751.
 31. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. 
Estrogen, menstrual cycle phases, and psychopathology 
in women suffering from schizophrenia. Psychol Med. 
2007;37(10):1427–1436.
 32. Choi SH, Kang SB, Joe SH. Changes in premenstrual symp-
toms in women with schizophrenia: a prospective study. 
Psychosom Med. 2001;63(5):822–829.
 33. Rubin  LH, Carter  CS, Drogos  L, Pournajafi-Nazarloo  H, 
Sweeney  JA, Maki  PM. Peripheral oxytocin is associated 
with reduced symptom severity in schizophrenia. Schizophr 
Res. 2010;124(1–3):13–21.
 34. Thompson  K, Sergejew  A, Kulkarni  J. Estrogen affects 
cognition in women with psychosis. Psychiatry Res. 
2000;94(3):201–209.
 35. Gleeson PC, Worsley R, Gavrilidis E, et al. Menstrual cycle 
characteristics in women with persistent schizophrenia. Aust 
N Z J Psychiatry. 2016;50(5):481–487.
 36. Hsiao MC, Hsiao CC, Liu CY. Premenstrual symptoms and 
premenstrual exacerbation in patients with psychiatric disor-
ders. Psychiatry Clin Neurosci. 2004;58(2):186–190.
 37. Herceg M, Puljić K, Sisek-Šprem M, Herceg D. Influence of 
hormonal status and menstrual cycle phase on psychopatol-
ogy in acute admitted patients with schizophrenia. Psychiatr 
Danub. 2018;30 (Suppl 4):175–179.
 38. Addington  DE, McKenzie  E, Wang  J. Validity of hospital 
admission as an outcome measure of services for first-episode 
psychosis. Psychiatr Serv. 2012;63(3):280–282.
 39. Andrew  A, Knapp  M, McCrone  P, Parsonage  M, 
Trachtenberg  M. Effective Interventions in Schizophrenia the 
Economic Case: A  Report Prepared for the Schizophrenia 
Commission. London, UK: Personal Social Services Research 
Unit, London School of Economics and Political Science; 2012.
 40. Fehring RJ, Schneider M, Raviele K. Variability in the phases 
of the menstrual cycle. J Obstet Gynecol Neonatal Nurs. 
2006;35(3):376–384.
 41. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. 
A role for estrogen in schizophrenia: clinical and preclinical 
findings. Int J Endocrinol. 2015;2015:615356.
 42. Riecher-Rossler  A, Hafner  H, Dutsch-Strobel  A, 
Stumbaum  M. Gonadal function and its influence on psy-
chopathology. A  comparison of schizophrenic and non-
schizophrenic female inpatients. Arch Womens Ment Health. 
1998;1:15–26.
 43. Riecher-Rössler  A, Häfner  H, Stumbaum  M, Maurer  K, 
Schmidt R. Can estradiol modulate schizophrenic symptom-
atology? Schizophr Bull. 1994;20(1):203–214.
 44. Riecher-Rössler  A, Häfner  H, Dütsch-Strobel  A, et  al. 
Further evidence for a specific role of estradiol in schizophre-
nia? Biol Psychiatry. 1994;36(7):492–494.
 45. Bedford NJ, David AS. Denial of illness in schizophrenia as 
a disturbance of self-reflection, self-perception and insight. 
Schizophr Res. 2014;152(1):89–96.
 46. Taffe  J, Dennerstein  L. Retrospective self-report compared 
with menstrual diary data prospectively kept during the men-
opausal transition. Climacteric. 2000;3(3):183–191.
 47. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) 
inhibitor. Endocr Rev. 2001;22(6):724–763.
 48. González-Blanco  L, Greenhalgh  AMD, Garcia-Rizo  C, 
Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin con-
centrations in antipsychotic-naïve patients with schizophre-
nia and related disorders: a meta-analysis. Schizophr Res. 
2016;174(1-3):156–160.
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sbz030/5487599 by King's C
ollege London user on 05 N
ovem
ber 2019
Page 13 of 13
Perimenstrual Exacerbation of Psychosis
 49. Karadag  F, Akdeniz  F, Erten  E, et  al. Menstrually related 
symptom changes in women with treatment-responsive bipo-
lar disorder. Bipolar Disord. 2004;6(3):253–259.
 50. Leibenluft  E, Ashman  SB, Feldman-Naim  S, Yonkers  KA. 
Lack of relationship between menstrual cycle phase and 
mood in a sample of women with rapid cycling bipolar disor-
der. Biol Psychiatry. 1999;46(4):577–580.
 51. Rasgon  N, Bauer  M, Glenn  T, Elman  S, Whybrow  PC. 
Menstrual cycle related mood changes in women with bipolar 
disorder. Bipolar Disord. 2003;5(1):48–52.
 52. Rasgon N, Bauer M, Grof P, et al. Sex-specific self-reported 
mood changes by patients with bipolar disorder. J Psychiatr 
Res. 2005;39(1):77–83.
 53. Perich TA, Roberts G, Frankland A, et al. Clinical characteris-
tics of women with reproductive cycle-associated bipolar dis-
order symptoms. Aust N Z J Psychiatry. 2017;51(2):161–167.
 54. Payne JL, Roy PS, Murphy-Eberenz K, et al. Reproductive 
cycle-associated mood symptoms in women with 
major depression and bipolar disorder. J Affect Disord. 
2007;99(1–3):221–229.
 55. Shivakumar  G, Bernstein  IH, Suppes  T, et  al.; Stanley 
Foundation Bipolar Network. Are bipolar mood symptoms 
affected by the phase of the menstrual cycle? J Womens 
Health (Larchmt). 2008;17(3):473–478.
 56. Dias  RS, Lafer  B, Russo  C, et  al. Longitudinal follow-up 
of bipolar disorder in women with premenstrual exac-
erbation: findings from STEP-BD. Am J Psychiatry. 
2011;168(4):386–394.
 57. Sit  D, Seltman  H, Wisner  KL. Menstrual effects on mood 
symptoms in treated women with bipolar disorder. Bipolar 
Disord. 2011;13(3):310–317.
 58. Marsh  WK, Ketter  TA, Crawford  SL, Johnson  JV, Kroll-
Desrosiers AR, Rothschild AJ. Progression of female repro-
ductive stages associated with bipolar illness exacerbation. 
Bipolar Disord. 2012;14(5):515–526.
 59. Weston J, Speroni KG, Ellis T, Daniel MG. The effect of men-
struation on psychiatric hospitalization. J Psychosoc Nurs 
Ment Health Serv. 2012;50(7):39–43.
 60. Robakis TK, Holtzman J, Stemmle PG, Reynolds-May MF, 
Kenna HA, Rasgon NL. Lamotrigine and GABAA receptor 
modulators interact with menstrual cycle phase and oral con-
traceptives to regulate mood in women with bipolar disorder. 
J Affect Disord. 2015;175:108–115.
 61. Blehar  MC, DePaulo  JR Jr, Gershon  ES, Reich  T, 
Simpson  SG, Nurnberger  JI Jr. Women with bipolar dis-
order: findings from the NIMH Genetics Initiative sample. 
Psychopharmacol Bull. 1998;34(3):239–243.
 62. Wesseloo  R, Kamperman  AM, Munk-Olsen  T, Pop  VJ, 
Kushner SA, Bergink V. Risk of  postpartum relapse in bipo-
lar disorder and postpartum psychosis: a systematic review 
and meta-analysis. Am J Psychiatry. 2016;173(2):117–127.
 63. Moglia ML, Nguyen HV, Chyjek K, Chen KT, Castaño PM. 
Evaluation of smartphone menstrual cycle tracking applica-
tions using an adapted applications scoring system. Obstet 
Gynecol. 2016;127(6):1153–1160.
 64. Palmier-Claus  JE, Ainsworth  J, Machin  M, et  al. The fea-
sibility and validity of ambulatory self-report of psychotic 
symptoms using a smartphone software application. BMC 
Psychiatry. 2012;12:172.
 65. de Boer J, Prikken M, Lei WU, Begemann M, Sommer I. The 
effect of raloxifene augmentation in men and women with 
a schizophrenia spectrum disorder: a systematic review and 
meta-analysis. npj Schizophr. 2018;4(1):1.
 66. Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treat-
ment-resistant schizophrenia: a large-scale randomized-con-
trolled trial in women of child-bearing age. Mol Psychiatry. 
2015;20(6):695–702.
 67. Herzog  AG. Catamenial epilepsy: update on prevalence, 
pathophysiology and treatment from the findings of the NIH 
progesterone treatment trial. Seizure. 2015;28:18–25.
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sbz030/5487599 by King's C
ollege London user on 05 N
ovem
ber 2019
